Mead Johnson Nutrition Co.

BASEL, Switzerland--(BUSINESS WIRE)-- TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors. Both bring extensive careers in the strategic, financial and corporate development aspects of building leading biotechnology companies. Together, they will contribute to TOLREMO’s further growth and operational execution as the company advances its lead candidate, TT125-802, designed to prevent transcriptional cancer drug resistance, through a Phase 1 first-in-human clinical trial. "We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO. “Jeff's extensive leadership experience and Mike's expertise in financial strategy within the life sciences sector are valuable assets as we continue our mission to overcome transcriptional drug resistance to a broad spectrum of targeted cancer treatments.” "Joining TOLREMO's board is an opportunity to contribute to a company making significant strides toward surmounting a universal problem for current and future targeted cancer therapies. I am eager to support TOLREMO in its clinical stage as it advances TT125-802 and help shape the company’s corporate strategy to ensure the team’s scientific knowledge is translated into tangible benefits for patients," said Jeff Jonkers, new board member at TOLREMO. “As a new member of the TOLREMO board, I look forward to applying my experience in guiding companies through critical growth phases to contribute to the company’s strategic financial perspective as we aim to maximize the potential of TT125-802,” said Mike Sherman, new board member at TOLREMO. Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry. He has served as the President and CEO as well as a Director of Belharra Therapeutics since 2021, and he is currently a member of the Board of Directors of California Life Sciences. Prior to this, Jeff served as the CEO of Ambys Medicines, President of NGM Pharmaceuticals, and Senior Vice President, Corporate and Business Development at Theravance Biopharma. His other executive roles include CBO of Satori Pharmaceuticals, Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene, as well as multiple leadership positions in the business development and legal groups at Genentech. Jeff began his career at Wilson Sonsini, representing clients in the life science and high-tech industries. Jeff holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews, and a B.A. from Claremont McKenna College. Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership. He currently serves as Board Chair at Chimerix, Inc. and as a Board Director at Werewolf Therapeutics. Prior to this, Mike was the CEO of Chimerix, where he led the company's shift from antivirals to oncology, including the FDA approval and sale of TEMBEXA® and the progression of a Phase 3 glioma trial for its lead oncology drug. Before Chimerix, he was the CEO of Endocyte, transforming its market capitalization from $200 million to a $2.1 billion acquisition by Novartis in 2018. This transformation involved pipeline re-prioritization, the acquisition of PLUVICTO®, and the execution of a Phase 3 regulatory and clinical strategy. Mike’s tenure at Endocyte originally began in 2006 as CFO, where he contributed to its IPO and various financings. His earlier career included executive roles at Guidant Corporation, a cardiovascular device manufacturer later acquired by Boston Scientific Corporation. Mike’s previous board experiences include positions at BioSpecifics Technologies, Inc., Mead Johnson Nutrition, and service as the former Chairman of the Board of Trustees for the Children’s Museum of Indianapolis. Mike holds a B.A. in Economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, where he graduated as a Tuck Scholar. About TOLREMO TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.

DUBLIN, March 12, 2024 /PRNewswire/ -- The "Global Personalized Retail Nutrition and Wellness Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. Global Personalized Retail Nutrition and Wellness Market projects significant growth from USD 2.42 billion in 2023 to USD 3.67 billion by 2028. This notable market expansion is attributed to a Compound Annual Growth Rate (CAGR) of 8.67%. Market Overview & Dynamics This detailed industry analysis reveals key insights into market dynamics that include a wide array of macro and micro-economic factors impacting the sector. The report examines how emotional and rational decisions of stakeholders influence market trends and price signals beyond the conventional economic forces of supply and demand. Analytical Market Segmentations The market is dissected by Recommendation, with segments including Continuous, Fixed, and Repeat recommendations Applications Segments cover targeted demographics such as Children, Female, and Male consumers Geographically, the study covers in-depth data from key regions such as the Americas, Europe, Middle-East & Africa, and Asia-Pacific Company and Country Analysis This analysis offers a critical view of competitor strategies within the market, showcasing financial performance analyses of listed companies and recent developmental strategies. Furthermore, the study encompasses detailed insights into specific countries, investigating the market from a granular perspective. Strategic Tools: Competitive Quadrant & Ansoff Analysis The report features innovative tools like the Competitive Quadrant and Ansoff Analysis to strategically analyze market players and provide a roadmap for industry growth. Factors such as new product launches, growth strategies, and market share expansion play a central role in this extensive analysis. Impact of Covid-19 Underpinning this study is an evaluative look at the effects of the Covid-19 pandemic on the Global Personalized Retail Nutrition and Wellness Market. The pandemic's repercussions have prompted market adjustments and strategic shifts within the industry. Regulatory Landscape Key regulatory frameworks across various regions and their implications on the sector are thoroughly discussed, ensuring readers are well-informed on the compliance requirements affecting market operations. Competitive Analysis The report encompasses an exhaustive competitive analysis, providing proprietary tools to benchmark companies' performance and industry placement. Comprehensive Market Insights Potential market entrants and existing players will discover a wealth of information, including historical data, current market trends, and forward-looking projections. The report's in-depth analysis offers a foundational understanding of the parent industry and vital market dynamics. Investors, stakeholders, and industry specialists are poised to gain a strategic edge from this report, which serves as a testament to the burgeoning Personalized Retail Nutrition and Wellness sector and its diverse market segments. Market Dynamics Drivers Growing Consumer Awareness of Health and Wellness Rising Geriatric Population and Prevalence of Several Disorders Restraints High Cost of Equipment and Difficulty in Maintaining Patient Database Opportunities Development in Metabolic Profiling Technologies Rising Adoption of Devices to Track Health Data Growing Trend of Customized Diet Plans Challenges Lack of Research Activities concerning Nutrigenomics Companies Mentioned Bactolac Pharmaceutical, Inc. Balchem Inc. Bayer Ag Baze Labs GmbH Care/of. (Noho Health Inc.) Cargill, Inc. DNAfit Life Sciences Ltd. DuPont de Nemours, Inc. General Mills, Inc. GSK PLC Habit Food Personalized, LLC Habit LLC Herbalife Nutrition Ltd. Mead Johnson & Company, LLC Metagenics, Inc. Nature's Bounty, Inc. Noom, Inc. Nutritional genomics Pfizer, Inc. Vitamin Packs, Inc. Wellness Coaches USA, LLC For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

New research has shown how a complex component of milk that can be added to infant formula has been shown to confer long-term cognitive benefits, including measures of intelligence and executive function in children. Breast milk is widely acknowledged as the most beneficial nutrition for infants, but many families face medical or logistical challenges in breastfeeding. In the U.S., just 45% of infants continue to be exclusively breastfed at 3 months of age, according to the Centers for Disease Control. For decades, researchers have sought to create a viable complement or alternative to breast milk to give children their best start for healthy development. New research out of the University of Kansas has shown how a complex component of milk that can be added to infant formula has been shown to confer long-term cognitive benefits, including measures of intelligence and executive function in children. The research by John Colombo, KU Life Span Institute director and investigator, along with colleagues at Mead Johnson Nutrition and in Shanghai, China, adds to the growing scientific support for the importance of ingredients found in milk fat globule membrane (MFGM) in early human development. The study, which was published in the Journal of Pediatrics, showed that feeding infants formula supplemented with MFGM and lactoferrin for 12 months raised IQ by 5 points at 5 ½ years of age. The effects were most evident in tests of children's speed of processing information and visual-spatial skills. Significant differences were also seen in children's performance on tests of executive function, which are complex skills involving rule learning and inhibition. All forms of mammalian milk contain large fat globules that are surrounded by a membrane composed of a variety of nutrients important to human nutrition and brain development, Colombo said. When milk-based infant formula is manufactured, the membrane has typically been removed during processing. "No one thought much about this membrane," Colombo said, "until chemical analyses showed that it's remarkably complex and full of components that potentially contribute to health and brain development." The 2023 study was a follow-up to one that Colombo also co-wrote with colleagues in Shanghai, China, published in the Journal of Pediatrics in 2019. That study showed that babies who were fed formula with added bovine MFGM and lactoferrin had higher scores on neurodevelopmental tests during the first year and on some aspects of language at 18 months of age. The global nutrition research community has been looking at MFGM for about a decade, Colombo said. Because the membrane is made up of several different components, it isn't known whether one of the components is responsible for these benefits, or whether the entire package of nutrients act together to improve brain and behavioral development. These benefits were seen in children long after the end of formula feeding at 12 months of age. "This is consistent with the idea that early exposure to these nutritional components contribute to the long-term structure and function of the brain," said Colombo, who has spent much of his career researching the importance of early experience in shaping later development.